Martini Gregory S. 4

What Happened

• Gregory S. Martini, Chief Financial Officer of Kyverna Therapeutics (KYTX), was granted 325,000 derivative shares (reported as an award/acquisition at $0.00) on May 18, 2026. The grant carries no immediate cash purchase price; the filing reports the award as a derivative security rather than an open-market buy or sale.

Key Details

• Transaction date: May 18, 2026; SEC filing date: May 20, 2026 (filed within the typical two-business-day Form 4 window).
• Grant size and price: 325,000 shares, $0.00 per share (derivative award).
• Shares owned after transaction: Not specified in the provided filing extract.
• Vesting (footnote): 1/4 of the shares vest on May 18, 2027, then 1/48 of the total grant vests each month thereafter, subject to continuous service through each vesting date.
• No indication of a sale, cash exercise, tax withholding sale, or 10b5-1 plan in the provided details.

Context

• This is a compensation-related award (derivative grant) subject to multi-year vesting, not an immediate market purchase or sale. Because of the vesting schedule, the shares are not fully exercisable/owned immediately; they become available over time if the CFO remains in service. Such grants are common for executive compensation and do not by themselves indicate a purchase-based bullish signal or a sale-based liquidity event.